Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151108 | 0.81 | DHFR (0.31) | — | |
| SCHEMBL13106286 | 0.80 | L3MBTL1 (0.43) | CHRM4MCHR1NMT1L3MBTL1 | |
| SCHEMBL13106187 | 0.76 | CHRM4 (0.41) | CHRM4MCHR1NMT1L3MBTL1 | |
| SCHEMBL13106332 | 0.75 | L3MBTL1 (0.42) | CHRM4MCHR1NMT1L3MBTL1 | |
| SCHEMBL13106276 | 0.72 | CHRM4 (0.43) | CHRM4MCHR1NMT1 | |
| SCHEMBL17348186 | 0.72 | ADORA2A (0.41) | CHRM4LMNAMCHR1 | |
| SCHEMBL15341789 | 0.69 | RAB9A (0.37) | EGLN1CHRM4LMNAMCHR1L3MBTL1 | |
| SCHEMBL22357763 | 0.69 | LMNA (0.37) | CHRM4LMNATP53L3MBTL1 | |
| SCHEMBL13106271 | 0.68 | POLB (0.46) | CHRM4LMNAMCHR1HTT | |
| SCHEMBL13106334 | 0.68 | MCHR1 (0.47) | CHRM4LMNAMCHR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE, ACE2, SARS1 | EGLN1 2713/4885CHRM4 3087/4885LMNA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.